Arrowstreet Capital’s iRadimed IRMD Stock Holding History

Arrowstreet Capital’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.49M	Buy	15,445 +9,136	+145%	+$914K	﹤0.01%	1466
2025 Q4	$614K	Buy	+6,309	New	+$541K	﹤0.01%	1650
2022 Q2	–	Sell	-17,149	Closed	-$769K	–	1327
2022 Q1	$769K	Sell	17,149 -821	-5%	-$38K	﹤0.01%	974
2021 Q4	$830K	Buy	+17,970	New	+$725K	﹤0.01%	1195
2018 Q4	–	Sell	-23,884	Closed	-$887K	–	1411
2018 Q3	$887K	Buy	+23,884	New	+$644K	﹤0.01%	821

Other funds holding IRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital's IRMD Position: Q1 2026 in Review

Arrowstreet Capital increased its iRadimed (IRMD) stake by 145% in Q1 2026, buying an estimated $914K and bringing the position to 15,445 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1466.

Arrowstreet Capital first reported a position in IRMD in Q3 2018 and has held it in 5 quarters since. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

Arrowstreet Capital held 15,445 shares of iRadimed worth $1.49M as of Q1 2026.
Arrowstreet Capital bought 9,136 iRadimed shares in Q1 2026, an estimated $914K.
iRadimed made up ﹤0.01% of Arrowstreet Capital's portfolio in Q1 2026, its #1466 holding.
Arrowstreet Capital first reported a position in iRadimed in Q3 2018 and has held it in 5 quarters since.
228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.